|
[1] LOZANO R,NAGHAVI M,FOREMAN K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990and 2010:A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.
|
|
[2] ADOLPH TE,GRANDER C,MOSCHEN AR,et al. Liver-microbiome axis in health and disease[J]. Trends Immunol,2018,39(9):712-723.
|
|
[3] CHOU HH,CHIEN WH,WU LL,et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A,2015,112(7):2175-2180.
|
|
[4] PRENDERGAST AJ,KLENERMAN P,GOULDER PJ. The impact of differential antiviral immunity in children and adults[J].Nat Rev Immunol,2012,12(9):636-648.
|
|
[5] PROTZER U,MAINI MK,KNOLLE PA. Living in the liver:Hepatic infections[J]. Nat Rev Immunol,2012,12(3):201-213.
|
|
[6] MCCLARY H,KOCH R,CHISARI FV,et al. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines[J]. J Virol,2000,74(5):2255-2264.
|
|
[7] WOHLLEBER D,KASHKAR H,GARTNER K,et al. TNF-induced target cell killing by CTL activated through cross-presentation[J]. Cell Rep,2012,2(3):478-487.
|
|
[8] EBERT G,PRESTON S,ALLISON C,et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus[J].Proc Natl Acad Sci U S A,2015,112(18):5797-5802.
|
|
[9] PEERIDOGAHEH H,MESHKAT Z,HABIBZADEH S,et al.Current concepts on immunopathogenesis of hepatitis B virus infection[J]. Virus Res,2018,245:29-43.
|
|
[10] CHISARI FV,FERRARI C. Hepatitis B virus immunopathogenesis[J]. Annu Rev Immunol,1995,13:29-60.
|
|
[11] XIA Y,STADLER D,LUCIFORA J,et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form,cccDNA,without cytolysis[J].Gastroenterology,2016,150(1):194-205.
|
|
[12] FOUTS DE,TORRALBA M,NELSON KE,et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease[J]. J Hepatol,2012,56(6):1283-1292.
|
|
[13] SENDER R,FUCHS S,MILO R. Revised estimates for the number of human and bacteria cells in the body[J]. PLo S Biol,2016,14(8):e1002533.
|
|
[14] ATARASHI K,HONDA K. Microbiota in autoimmunity and tolerance[J]. Curr Opin Immunol,2011,23(6):761-768.
|
|
[15] LIU JQ,ZHOU SM. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. J Clin Hepatol,2017,33(12):2453-2456.(in Chinese)刘嘉琪，周少明．非酒精性脂肪性肝病肠道菌群的研究进展[J]．临床肝胆病杂志，2017,33(12):2453-2456.
|
|
[16] LIU XY,KONG GM,QIAN F. Research progress of probiotics in the treatment of inflammatory bowel disease[J]. Chin J Med Offic,2018,46(7):840-842.(in Chinese)刘心意，孔桂美，钱锋．益生菌治疗炎症性肠病研究进展[J]．临床军医杂志，2018,46(7):840-842.
|
|
[17] ZHANG J,FENG Z,LIU P,et al. Research progress on interaction between intestinal flora and liver transplantation[J].Ogran Transplantation,2017,8(5):399-401.(in Chinese)张静，冯哲，刘鹏，等．肠道菌群与肝移植相互作用研究进展[J]．器官移植，2017,8(5):399-401.
|
|
[18] GHOSH G,JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol,2019,9(2):257-267.
|
|
[19] XING HC,LI LJ,XU KJ,et al. Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia-reperfusion injury[J]. J Gastroenterol Hepatol,2006,21(4):647-656.
|
|
[20] CHEN Y,YANG F,LU H,et al. Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology,2011,54(2):562-572.
|
|
[21] HUANG XY,LI GP,KOU JG,et al. Relationship between intestinal dysbacteriosis and Child-Pugh classification in patients with cirrhosis[J]. J Clin Hepatol,2015,31(3):392-395.(in Chinese)黄晓宇，李刚平，寇继光，等．肝硬化患者肠道菌群失调与Child-Pugh分级的关系[J]．临床肝胆病杂志，2015,31(3):392-395.
|
|
[22] CHEN Y,CHEN Z,GUO R,et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection[J]. Diagn Microbiol Infect Dis,2011,70(4):492-498.
|
|
[23] CAMPION D,GIOVO I,PONZO P,et al. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis[J]. World J Gastroenterol,2019,11(6):489-512.
|
|
[24] RIORDAN SM,WILLIAMS R. Gut flora and hepatic encephalopathy in patients with cirrhosis[J]. N Engl J Med,2010,362(12):1140-1142.
|
|
[25] GARCIA-TSAO G,WIEST R. Gut microflora in the pathogenesis of the complications of cirrhosis[J]. Best Pract Res Clin Gastroenterol,2004,18(2):353-372.
|
|
[26] PIANO S,BROCCA A,ANGELI P. Renal function in cirrhosis:A critical review of available tools[J]. Semin Liver Dis,2018,38(3):230-241.
|
|
[27] KANG Y,CAI Y. Gut microbiota and hepatitis-B-virusinduced chronic liver disease:Implications for faecal microbiota transplantation therapy[J]. J Hosp Infect,2017,96(4):342-348.
|
|
[28] FRAZIER TH,DIBAISE JK,McCLAIN CJ. Gut microbiota,intestinal permeability,obesity-induced inflammation,and liver injury[J]. JPEN J Parenter Enteral Nutr,2011,35(Suppl 5):14s-20s.
|
|
[29] SEKI E,SCHNABL B. Role of innate immunity and the microbiota in liver fibrosis:Crosstalk between the liver and gut[J]. J Physiol,2012,590(3):447-458.
|
|
[30] BORRELLI A,BONELLI P,TUCCILLO FM,et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches[J]. Redox Biol,2018,15:467-479.
|
|
[31] GAO K,LIU L,WANG HF. Advances in immunomodulation of microbial unmethylated CpG DNA on animal intestinal tract-a review[J]. Acta Microbiol Sin,2015,55(5):543-550.(in Chinese)高侃，刘丽，汪海峰．微生物未甲基化CpG DNA对动物肠道的免疫调节作用[J]．微生物学报，2015,55(5):543-550.
|
|
[32] IGNACIO A,MORALES CI,CAMARA NO,et al. Innate sensing of the gut microbiota:Modulation of inflammatory and autoimmune diseases[J]. Front Immunol,2016,7:54.
|
|
[33] VARAKANAHALLI S,SHARMA BC,SRIVASTAVA S,et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver:A double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo[J]. Eur J Gastroenterol Hepatol,2018,30(8):951-958.
|
|
[34] LIU GY,CHEN HH,WANG X,et al. Advances in research on antibiotic resistance of Bifidobacteria[J]. Chin J Microecol,2019,31(3):360-364.(in Chinese)刘桂扬，陈华海，王欣，等．双歧杆菌抗生素耐药性研究进展[J]．中国微生态学杂志，2019,31(3):360-364.
|
|
[35] SCHUIJT TJ,LANKELMA JM,SCICLUNA BP,et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia[J]. Gut,2016,65(4):575-583.
|
|
[36] GEVA-ZATORSKY N,SEFIK E,KUA L,et al. Mining the human gut microbiota for immunomodulatory organisms[J].Cell,2017,168(5):928-943.
|
|
[37] GUNALTAY S,RADEMACHER L,HULTGREN E,et al. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis[J]. World J Gastroenterol,2017,23(7):1319-1324.
|
|
[38] NISHIDA A,IMAEDA H,OHNO M,et al. Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis[J]. J Gastroenterol,2017,52(4):476-482.
|
|
[39] REN YD,YE ZS,YANG LZ,et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen(HBe Ag)clearance in patients with positive HBe Ag after long-term antiviral therapy[J]. Hepatology,2017,65(5):1765-1768.
|
DownLoad: